Status:
COMPLETED
Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis
Lead Sponsor:
Pfizer
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The study is a randomized, double blinded, vehicle and active comparator controlled, multiple dose study in subjects with chronic plaque psoriasis. The study will have approximately 15 completers. Eac...
Eligibility Criteria
Inclusion
- Psoriasis vulgaris in a chronic stable phase and with a plaque area of mild to moderate severity sufficient for six treatment fields located in up to three plaque areas
- Target lesion(s) should be on the trunk or extremities (excluding palms/soles).
Exclusion
- History of skin sensitivity to topical prescription or non prescription products such as creams, lotions and cosmetics
- Psoriasis guttata, psoriasis punctata, psoriasis erythrodermatica, and pustular psoriasis
- Treatment with any biologics within 3 months prior to Day 1 of the study and during the study
Key Trial Info
Start Date :
April 24 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 20 2019
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT03469336
Start Date
April 24 2018
End Date
March 20 2019
Last Update
June 25 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Rothaar Studien GmbH
Berlin, Germany, 10783
2
bioskin GmbH
Hamburg, Germany, 20095